NicOx S.A Company Profile

14:04 EDT 24th March 2018 | BioPortfolio

NicOx is a product-driven biopharmaceutical company dedicated to the development of nitric oxide-donating drugs to meet unmet medical needs.NicOx is targeting the therapeutic areas of inflammation and cardiovascular disease.The Company’s resources are focused on its two lead compounds in late stage development for the treatment of osteoarthritis and Peripheral Arterial Obstructive Disease (PAOD).NicOx aims to build itself into a fully integrated biopharmaceutical company through focused investment in in-house research and development programs and potentially through in-licensing and by making select acquisitions in its core therapeutic domains of inflammation and cardiovascular disease.


Gaïa II - 2455 Route des DolinesB.P. 313
Sophia Antipolis Cedex
06 906


Phone: 33 (0)4 92 38 70 20
Fax: 33 (0)4 92 38 70 30

News Articles [29 Associated News Articles listed on BioPortfolio]

Nicox, Re-Vana enter collaboration agreement

Nicox and Re-Vana Therapeutics have entered a research collaboration to study the possibility of combining Nicox’s stand-alone nitric oxide donors with Re-Vana’s EyeLief drug delivery platform for...

NicOx partners on novel S-R ophthalmic formulation

French biotech firm NicOx has entered into a research collaboration with Northern Ireland-based Re-Vana…

NicOx fills newly-created position of head of development

French ophthalmic company NicOx today announced the appointment of Tomas Navratil as vice president and…

NicOx rockets on Vyzulta approval

French eye-care specialist NicOx was trading 29% up at 11.14 euros mid-way through Friday’s trading…

Nicox, Bausch + Lomb restructure Vyzulta financial terms

Nicox and Bausch + Lomb have agreed to new financial terms for Vyzulta, which includes an additional $20 million in potential milestone payments, according to a press release.The original global licen...

Nicox reports third quarter highlights

Nicox had cash and cash equivalents of 47.1 million euros as of Sept. 30 compared with 20.4 million euros as of June 30, according to a company press release.The company reported no revenues for the t...

FDA Okays Treatment For Patients With Glaucoma Or Ocular Hypertension

NewsBausch + Lomb and Nicox announce FDA approval of Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%. Nicox will receive $17.5 million from Bausch + Lomb and will make a $15 million pay...

NICOX : Number of voting rights as of December 31, 2017

Nicox SASociété anonyme with a registered capital of € 29,169,338 Head Office:DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 ...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [3 Associated Companies listed on BioPortfolio]

NicOx SA

NicOx aims to achieve profitability and growth through the research and development of nitric oxide therapeutics. NicOx begins its development process by taking well-known drugs and enhancing them wit...

NicOx S.A

NicOx is a product-driven biopharmaceutical company dedicated to the development of nitric oxide-donating drugs to meet unmet medical needs.NicOx is targeting the therapeutic areas of inflammation and...


More Information about "NicOx S.A" on BioPortfolio

We have published hundreds of NicOx S.A news stories on BioPortfolio along with dozens of NicOx S.A Clinical Trials and PubMed Articles about NicOx S.A for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NicOx S.A Companies in our database. You can also find out about relevant NicOx S.A Drugs and Medications on this site too.

Quick Search


Relevant Topics

Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Corporate Database Quicklinks

Searches Linking to this Company Record